Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.48 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.48 |
| ▸ | MLYCD | O95822 | 2/20 | 0.48 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.47 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 2/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.45 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | RXRA | P19793 | 5/20 | 0.43 |
| ▸ | RXRB | P28702 | 4/20 | 0.43 |
| ▸ | RXRG | P48443 | 4/20 | 0.43 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.42 |
| ▸ | LTB4R2 | Q9NPC1 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10688205 | 0.87 | RXRA (0.53) | NR1H2NR1H3MLYCDSMN1; SMN2RXRA | |
| SCHEMBL3981981 | 0.87 | PLA2G4B (0.53) | NR1H2NR1H3MLYCDPLA2G4BPPARD | |
| SCHEMBL3979291 | 0.85 | NR1H2 (0.51) | NR1H2NR1H3MLYCDSMN1; SMN2LMNA | |
| SCHEMBL3979444 | 0.83 | PPARD (0.50) | NR1H2NR1H3PLA2G4BPPARDPPARG | |
| SCHEMBL11683055 | 0.82 | PLA2G4B (0.61) | PLA2G4BTBXAS1SMN1; SMN2LTB4RLTB4R2 | |
| SCHEMBL3984175 | 0.82 | PLA2G4B (0.45) | NR1H2NR1H3PLA2G4BPPARDPPARG | |
| SCHEMBL3978187 | 0.78 | NR1H2 (0.51) | NR1H2NR1H3MLYCDPPARGPPARA | |
| SCHEMBL3978193 | 0.78 | NR1H2 (0.51) | NR1H2NR1H3MLYCDPPARGPPARA | |
| SCHEMBL3978190 | 0.78 | NR1H2 (0.51) | NR1H2NR1H3MLYCDPPARGPPARA | |
| SCHEMBL11596764 | 0.78 | NR4A2 (0.54) | PLA2G4BTBXAS1SMN1; SMN2LTB4RLTB4R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7473705-B2 | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-01-06 | — | — | US | claimed |
| EP-1802566-B1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | claimed |
| EP-1802566-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | claimed |
| WO-2006037480-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | claimed |
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | claimed |
| US-7473705-B2 | Hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-01-06 | — | — | US | disclosed |
| EP-1802566-B1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-11-26 | — | — | EP | disclosed |
| EP-1802566-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-07-04 | — | — | EP | disclosed |
| WO-2006037480-A1 | HEXAFLUOROISOPROPANOL SUBSTITUTED ETHER DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2006-04-13 | — | — | WO | disclosed |
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | HOFFMANN-LA ROCHE INC. | 2006-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074115-A1 | Novel hexafluoroisopropanol substituted ether derivatives | NR1H3, NR1H2, NR1I2 | NR1H2 2/4885NR1H3 1/4885MLYCD 2588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.